The Canadian Press on MSN23h
FDA approves new painkiller that shows promise and challenges of opioid alternatives
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript
Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...
What to Know: FDA Approves Non-Opioid Pain Medication, Journavx
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
What to Know About Journavx, the Non-Opioid Pain Medication Just Approved by the FDA
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
Vertex (VRTX) Secures FDA Approval for Highly-Awaited Non-Opioid Painkiller
U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...
FDA Approves Vertex Pharma's JOURNAVX As The First Drug In A New Class Of Non-Opioid Pain Medicines
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
FDA approves new painkiller aimed at eliminating risks of addiction associated with opioids
WASHINGTON — Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and ...
5 things to know for Jan. 31: Plane collision, Confirmation hearings, Pain medicine, Japan sinkhole, FireAid benefit concerts
While America retains a gold standard for airline safety, there are stresses on the US air travel system that have been ...
New type of non-opioid pain medication approved by FDA
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. To ...
'Hope of a cure': Revolutionary gene-editing therapy for sickle cell approved for use on NHS
NHS officials estimate around 50 people a year will receive treatment now it has been approved for use for certain patients with severe sickle cell disease. | ITV National News ...
AbbVie Forecasts 2025 Profit Above Estimates on Newer Immunology Drugs
(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and ...